Biogen

BIIBNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$33.298 B

$225.36 +2.87%

Close of 22 Sept 2026

Revenue

$9.89B

#418 by revenue

Earnings

$1.29B

#322 by earnings

Shares outstanding

147,753,998

Latest filing cover page

P/E ratio

25.8

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#4Argenx SeARGX$59.8B
#5Revolution MedicinesRVMD$41.3B
#6BiogenBIIB$33.3B
#7BioNTech SEBNTX$25.3B
#8Neurocrine BiosciencesNBIX$14.5B

What if Biogen were worth as much as…

Open the what-if tool →

Gold $30.2T

$204,623.70

Per share 908× higher

Bitcoin $1.74T

$11,787.53

Per share 52.3× higher

Nvidia $5.52T

$37,330.75

Per share 166× higher

Or at a round number

$50.0B $100.0B $200.0B $500.0B

Where these numbers come from

Share counts and financials for Biogen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.